Association of Ex Vivo Drug Response (EVDR) and Clinical Outcome in Ovarian Cancer

Who can take part

• Minimum age 18 years
• Signed informed consent form
• Confirmed diagnosis of ovarian cancer except low grade serous, clear cell and mucinous histology
• Where patients are treatment naïve, patients need to have disease stage FIGO (International Federation of Gynecology and Obstetrics) III or FIGO IV
• Patient is expected to receive primary chemotherapy/maintenance after initial surgical debulking or a further line of systemic therapy in the relapsed setting according to treatment guidelines
• Feasibility of collecting malignant ascites and/or pleural effusion during either primary debulking surgery or a routine drainage procedure prior to initiation of the first or next line of systemic therapy
• ECOG (Eastern Cooperative Oncology Group) stage 0-2

Who cannot take part

• Previously study participation
• Anticancer treatment or radiation therapy of the region which is to be drained or biopsied within the last 4 weeks
• Patient is treated with therapeutics not tested in the assay - with the exception of anti-VEGF (Vascular endothelial growth factor) therapy
• Known or suspected HIV or active Hepatitis B and/or C infection or active COVID-19 infection
• Patient unfit or not willing to receive any further systemic treatment
• Known pregnancy
• Sample quality criteria are not met (at least 250ml of ascites available, no signes of bacterial superinfection, no additives, at least 1% EpCAM (Epithelial Cell Adhesion Molecule) positive cells, viability at least 60%)